SLU-PP-332 is a synthetic small-molecule compound that has been investigated in preclinical research for its activity as an estrogen-related receptor (ERR) agonist.
Research interest centers on its role in mitochondrial bioenergetics and metabolic pathway modulation, making it a compound of interest in the study of energy expenditure mechanisms. Here’s what the research tells us about this novel compound.
Quick Summary:
- SLU-PP-332 is a synthetic ERR agonist investigated in preclinical research for its effects on mitochondrial bioenergetics and oxidative metabolism, with proposed mechanisms overlapping with metabolic adaptations associated with aerobic exercise training.
- Animal model studies have reported effects on fatty acid oxidation, resting energy expenditure, glucose homeostasis markers, and skeletal muscle oxidative fiber expression, with no serious adverse effects observed.
- SLU-PP-332 has not been evaluated in human clinical trials; its safety profile, pharmacokinetics, and efficacy in human populations remain uncharacterized.
Mechanism of Action in Research Models
SLU-PP-332 functions by activating estrogen-related receptors (ERRα, ERRβ, ERRγ), a family of nuclear receptors that regulate mitochondrial function and oxidative metabolism. In studied models, ERR activation has been associated with:
- Upregulation of fatty acid oxidation pathways
- Increased mitochondrial biogenesis and oxidative fiber expression in skeletal muscle
- Enhanced resting energy expenditure
- Modulation of glucose homeostasis markers
These mechanisms have drawn research interest due to their overlap with the metabolic adaptations observed in aerobic exercise training, making SLU-PP-332 a tool for studying exercise-mimetic pharmacology at the receptor level.
Preclinical Research Findings
Current evidence for SLU-PP-332 derives entirely from in vitro and animal model studies. No human clinical trial data are available at this time.
In one 2024 murine obesity model study, researchers administered SLU-PP-332 to both diet-induced obese and genetically obese mouse models. Findings included:
- Increased fatty acid oxidation and resting energy expenditure, consistent with aerobic exercise-like metabolic changes
- Treated animals exhibited approximately 12% reduction in body weight and accumulated significantly less fat mass relative to controls, with no observed change in food intake
- Improved glucose tolerance and reduced fasting insulin levels in obese models
- Reduced hepatic fat and triglyceride content
- No adverse effects on muscle tissue, liver enzymes, or pancreatic function markers were reported
Another 2023 skeletal muscle and endurance model study examined SLU-PP-332’s effects on skeletal muscle metabolism and physical performance metrics in mice.
Findings included a reported 70% increase in running time and 45% increase in running distance relative to controls, alongside increased mitochondrial oxidative fiber expression and upregulation of metabolic gene pathways associated with exercise adaptation.
Both studies were conducted by research teams including Dr. Thomas Burris and colleagues; human trials have not yet commenced.
Safety Data
Safety characterization of SLU-PP-332 is currently limited to preclinical models. In available animal studies, no serious adverse effects were identified at studied doses, with no observed hepatotoxicity, myotoxicity, or pancreatic dysfunction.
A comprehensive human safety profile has not been established, and the compound’s tolerability, pharmacokinetics, and long-term effects in humans remain unknown.
Open Research Questions
The published literature identifies several areas requiring further investigation before SLU-PP-332’s research profile can be more fully characterized:
- Replication of preclinical findings in human study populations
- Long-term safety and tolerability characterization
- Optimal dosing and administration parameters
- Pharmacokinetic profile in non-rodent models
- Specificity of ERR subtype engagement and downstream pathway effects
Research Context Summary
SLU-PP-332 represents a mechanistically distinct approach to studying metabolic pathway modulation via ERR agonism. Its preclinical profile demonstrates measurable effects on energy expenditure, lipid metabolism, and glucose homeostasis markers in animal models.
The compound remains at an early research stage with no human data available, and all findings should be interpreted within the context of preclinical limitations.